Newark, DE – Corrixr Therapeutics has announced the appointment of Hilary Malone as Chief Executive Office. About Corrixr Therapeutics: Corrixr Therapeutics is an oncology-focused biotherapeutics company developing targeted genetic medicines designed to disable the NRF2 pathway in lung, head and neck, and esophageal squamous cell cancers. Using a proprietary in vivo CRISPR/Cas gene editing platform delivered via proven lipid nanoparticle (LNP) technology with localized administration, the company aims to achieve precise engagement at the tumor site while minimizing off-target effects. Its preclinically validated lead program, CXR101, focuses on head and neck squamous cell carcinoma, the seventh leading cause of cancer in the U.S., where recurrence rates remain high despite current standard-of-care treatments. By disabling NRF2, Corrixrs approach is designed to reprogram the tumor microenvironment, disable drug resistance pathways, and enhance tumor cell stress responses to all standard treatments, ultimately improving safety, efficacy, and patient outcomes. The companys platform has broad potential applicability across more than 30 squamous cell carcinoma indications, positioning Corrixr Therapeutics as a pioneer in a new paradigm for treating solid tumors through precision gene editing.

For more information visit: https://www.corrixr.com/

Corrixr Therapeutics
550 S. College Avenue Suite 107
Newark, DE 19713
Phone: 302-623-5305
LinkedIn: https://www.linkedin.com/company/corrixrtherapeutics/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved